Bhavneesh Sharma: MD, MBA in Finance - NYU Stern

Unicycive Therapeutics $UNCY: Was a great trade last year after first CRL. FDA did not inspect the manufacturing facility, so second CRL. Expecting inspection soon and a two month review period, leading to approval by year end. Picked up again 2 weeks ago after second CRL. Stock up >6% today, looks like FDA inspection progress. #stocks #investing #biotech

Forte Biosciences $FBRX: closed today at approx 100% gain after recent spectacular vitiligo data. SA Investing group link in bio. #biotech #stocks #investing

AtaiBeckley $ATAI: Closed today at 32% gain in <2 weeks. My DCF SOTP PT was $10, so i believe it was acquired for cheap. Link to SA investing group in my bio. #biotech #stocks #investing.

The bull case on my newest biotech oncology BUY says the peak number is 2x what I model. I'm still a buyer. Because the debate everyone's having, does the drug work, got settled last week. The debate that actually decides the stock hasn't started: will doctors reach for it? BUY, ~45% upside. Full thesis, name and PT inside my SA investing group service. Link in Bio. #stocks #biotech #investing

Everyone saw "FDA rejection #2" and hit sell. I saw a mispriced repair story: the science is fine, the problem is fixable, and I've traded this exact name before and won. I'm long again. The ticker, the odds, and my DCF price target are with my Seeing Alpha investing group (Vasuda Healthcare Analytics) subscribers. Link in bio. #biotech #stocks #investing

New biotech position today: only company targeting this oncology mutation. A microcap with a first-in-class asset, a clean molecular moat, and one loud binary in front of it. The setup: → Base case ~$2. Bull case ~$15 , 10x+ upside on the tail. → Probability-weighted target ~$3.50 (~2.7x from here). → My four-method ensemble puts FDA approval odds at ~53%, with asymmetric payoff. The whole thesis rides on three catalysts: BICR confirming the ORR near 40% NDA submission FDA accepting a single-arm filing (targeted Q1 '27) Hit them and the re-rate is violent. Small starter. Long. Not investment advice. Position disclosed to Seeking Alpha investing group subscribers. #biotech #stocks

$FBRX latest winner. Up more than 100 pct in two days after vitiligo data. Trimmed today #biotech #stocks

GPT 5.5 Sol is also flagging all biotech, pharma, biology related research work like Fable. OpenAI fucked up... Please fix it. @OpenAI @sama #AI

@OpenAI Shitty new web version of ChatGPT, I am not unable to add custom plugins/connectors like FMP which I could do earlier in developer mode on web app. Claude web allows that easily. You also have non coder users who use it for research, etc. Please fix this issue and allow Web app to work smoothly with more connectors and plugins like those for financial datasets (FMP etc), Also allow users to add their own custom plugins using API keys, custom URLs etc. @sama

GPT-5.6: Frontier intelligence that scales with your ambition | OpenAI openai.com/index/gpt-5-6/

Want to share this little side-project which started as an interactive artifact to help my son (BS in business (finance) + CS student at NYU-Stern, Senior) about AI sector as investment. Turned out be better than I expected. Feel free to share, still working on improving it more (Stack = Harness (Claude Code), Orchestrer/Planner (Fable 5), Executor (Opus 4.8), Deployment: Replit) #AI. ai-stack-academy.replit.app

$MNPR: Closing remaining position at around 48% gain in 6 weeks. #stocks #biotech (original thesis: Monopar Therapeutics, MNPR: New long position Pivot to a de-risked late-stage asset: Monopar has rebuilt itself around ALXN1840, a once-daily oral copper agent for Wilson disease that hit its Phase 3 FoCus primary endpoint (3x copper mobilization vs. standard of care, LSM diff 2.18 µmol/L, p<0.0001), with an NDA targeted for mid-2026. The core bet is regulatory: AstraZeneca walked from the asset over the dNCC biomarker/copper-redistribution dispute (plus a $244M impairment), but new long-term neurological data rebuts that concern, we model 65% approval PoS of FDA NDA acceptance and approval and reads the walk-away as portfolio/timeline-driven, not a safety signal. Large underserved market, premium pricing: Wilson disease is dominated by toxic, poorly-tolerated legacy chelators; at $120K net price and 25% peak penetration the franchise supports approx. $500M peak sales with orphan exclusivity to 2038. Free optionality on top: The uPAR-targeted radiopharmaceutical platform (MNPR-101 antibody-based PET + Lu-177/Ac-225 therapy) is a long-volatility call option the market currently prices at roughly zero. Asymmetric setup with a hard floor: A fortress balance sheet ($137.5M cash, runway through 2027, ~$16/sh floor, zero debt) caps downside, while the scenarios (bull $155 / base $110 / bear $16) probability-weight to a $91 scenario-weighted PT (25/65/10), 35%-50% upside in six months.)

UBS raises its DRAM and NAND price forecasts DRAM prices are now expected to rise 32% QoQ in Q3 and 18% QoQ in Q4. NAND prices are expected to rise 30% QoQ in Q3 and 12% QoQ in Q4.

**Top 3 public companies set to benefit most from the SPHBM4 substrate boom:** 1. **Unimicron (Taiwan)** — Largest ABF substrate maker. SPHBM4’s high-layer (20-28+) routing, larger packages, and 20mm reach will drive massive volume and pricing power as complexity shifts to substrates. 2. **Ibiden (Japan)** — Key supplier of advanced high-density substrates for AI chips. Positioned for strong growth in premium, high-layer ABF as standard packaging houses adopt HBM. 3. **Samsung Electro-Mechanics (Korea)** — Major substrate player with glass substrate exposure. Benefits directly from democratized HBM, bigger substrates, and the pull-forward of glass tech. SPHBM4 moves the engineering burden from expensive silicon interposers to advanced substrates — exactly the tailwind these firms need.

@SemiAnalysis_ @Grok which are top 3 public companies (US or international) that stand to benefit the most from conceits described in above posts and why? See the whole thread above.

The Bottom Line: SPHBM4 shifts the complex engineering burden of AI chips. Instead of buying a hyper-expensive, proprietary "Silicon Interposer + ABF Substrate" combo, chipmakers will shift entirely to buying ultra-large, high-layer ABF or even pull forward the adoption of glass substrates as performance requirements are pushed directly onto the substrate layer. The substrate boom is just getting started. (6/6)

This last week JEDEC announced a new standard for SPHBM4: Standard Package High Bandwidth Memory (JESD330-4). It utilizes the same DRAM stacks as HBM4, but swaps in a different buffer die. The goal? Enable HBM assembly in standard packaging and break the AI Advanced Packaging bottleneck. (1/6)🧵

Fable 5 is God in frontend design. #AI

Nano Dimension ($NNDM): upcoming propose merger: Reviewed after report of activist Tang stake: I would pass on NNDM stock for now because the setup is more of a messy governance/cash-shell arbitrage than a clean investment. Tang’s stake adds pressure and optionality, but its competing proposal has no disclosed price or terms, so following Tang here means buying uncertainty, not a defined spread. The Infinite Epigenetics merger may create upside if investors accept the healthcare-AI story, but the $890M valuation for Infinite Epigenetics looks aggressive based on comparables without audited revenue, margin, reimbursement, and clinical-utility proof. Until either Tang offers a concrete superior deal or Infinite’s S-4 validates the business, the risk/reward is not compelling enough to buy. Infinite's founder also founded TEM, so will add to watchlist. No position. Not investment advice. #biotech #stocks

Fable is AGI. #AI

Good to have bought the dip in $ABVX after the malignancy scare, Another crisis alpha biotech winner for the portfolio, holding for M&A above $200. #biotech #stocks

$MNPR was a recent crisis alpha win, still holding some. #biotech #stocks